Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370

British Journal of Pharmacology

Volumn 171, Issue 19, 2014, Pages 4413-4424

  Jepps, T A ^a   Bentzen, B H ^a   Stott, J B ^b   Povstyan, O V ^b   Sivaloganathan, K ^b   Dalby Brown, W ^c   Greenwood, I A ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Institute of Cardiovascular Medicine and Science (ICMS)   (United Kingdom)

^c NEUROSEARCH A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,5 DIFLUOROPHENYL) N [6 [(4 FLUOROPHENYL)METHYLAMINO] 2 MORPHOLINO 3 PYRIDYL]ACETAMIDE; FLINDOKALNER; N MESITYLBICYCLO[2.2.1]HEPTANE 2 CARBOXAMIDE; N [1 (3 MORPHOLINO 4 YLPHENYL)ETHYL] 3 PHENYLACRYLAMIDE; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ4; POTASSIUM CHANNEL KCNQ5; POTASSIUM CHANNEL STIMULATING AGENT; RETIGABINE; TRYPTOPHAN; UNCLASSIFIED DRUG; 2-(3,5-DIFLUOROPHENYL)-N-(6-((4-FLUOROPHENYL)METHYLAMINO)-2-MORPHOLINO-3-PYRIDYL)ACETAMIDE; AMINOPYRIDINE DERIVATIVE; ANILIDE; BENZENEACETAMIDE DERIVATIVE; BICYCLO COMPOUND; ISOPROTEIN; N-MESITYBICYCLO(2.2.1)HEPTANE-2-CARBOXAMIDE; POTASSIUM CHANNEL KCNQ; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTERY DILATATION; ARTERY MUSCLE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; EC50; EMBRYO; HUMAN; HUMAN CELL; HYPERPOLARIZATION; MALE; MEMBRANE STEADY POTENTIAL; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RAT; RENAL ARTERY; SMOOTH MUSCLE FIBER; THORACIC AORTA; ANIMAL; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; IN VITRO STUDY; KIDNEY ARTERY; MUSCLE CELL; PHYSIOLOGY; WISTAR RAT;

AMINOPYRIDINES; ANILIDES; ANIMALS; AORTA, THORACIC; BENZENEACETAMIDES; BICYCLO COMPOUNDS; HEK293 CELLS; HUMANS; IN VITRO TECHNIQUES; KCNQ POTASSIUM CHANNELS; MALE; MESENTERIC ARTERIES; MUSCLE CELLS; PROTEIN ISOFORMS; RATS, WISTAR; RENAL ARTERY; VASODILATOR AGENTS;

EID: 84927778175     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12805     Document Type: Article

References (46)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
2. Bentzen BH, Schmitt N, Calloe K, Dalby-Brown W, Grunnet M, Olesen SP, (2006). The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology 51: 1068-1077.
3. Blom SM, Schmitt N, Jensen HS, (2010). Differential effects of ICA-27243 on cloned Kv7 channels. Pharmacology 86: 174-181.
4. Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, et al. (2010). Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75: 1817-1824.
5. Brueggemann LI, Kakad PP, Love RB, Solway J, Dowell ML, Cribbs LL, et al. (2012). Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy. Am J Physiol Lung Cell Mol Physiol 302: L120-L132.
6. Brueggemann LI, Mackie AR, Cribbs LL, Freda J, Tripathi A, Majetschak M, et al. (2014). Differential protein kinase C-dependent modulation of Kv7.4 and Kv7.5 subunits of vascular Kv7 channels. J Biol Chem 289: 2099-2111.
7. Chadha PS, Zunke F, Zhu HL, Davis AJ, Jepps TA, Olesen SP, et al. (2012a). Reduced KCNQ4-encoded voltage-dependent potassium channel activity underlies impaired β-adrenoceptor-mediated relaxation of renal arteries in hypertension. Hypertension 59: 877-884.
8. Chadha PS, Zunke F, Davis AJ, Jepps TA, Linders JT, Schwake M, et al. (2012b). Pharmacological dissection of Kv7.1 channels in systemic and pulmonary arteries. Br J Pharmacol 166: 1377-1387.
9. Chadha PS, Jepps TA, Carr G, Stott JB, Zhu HL, Cole WC, et al. (2014). Contribution of Kv7.4/Kv7.5 heteromers to intrinsic and calcitonin gene-related peptide-induced cerebral reactivity. Arterioscler Thromb Vasc Biol 34: 887-893.
10. Dailey JW, Cheong JH, Ko KH, Adams-Curtis LE, Jobe PC, (1995). Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Neurosci Lett 195: 77-80.
11. Dalby-Brown W, Jessen C, Hougaard C, Jensen ML, Jacobsen TA, Nielsen KS, et al. (2013). Characterization of a novel high potency positive modulator of Kv7 channels. Eur J Pharmacol 709: 52-63.
12. French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, et al. (2011). Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76: 1555-1563.
13. Ipavec V, Martire M, Barrese V, Taglialatela M, Currò D, (2011). Kv7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus. Pharmacol Res 64: 397-409.
14. + channel in murine gastrointestinal smooth muscles. Am J Physiol Gastrointest Liver Physiol 297: G107-G115.
15. Jepps TA, Chadha PS, Davis AJ, Harhun MI, Cockerill GW, Olesen SP, et al. (2011). Downregulation of Kv7.4 channel activity in primary and secondary hypertension. Circulation 124: 602-611.
16. Jepps TA, Olesen SP, Greenwood IA, (2013). One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders. Br J Pharmacol 168: 19-27.
17. Joshi S, Sedivy V, Hodyc D, Herget J, Gurney AM, (2009). KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle. J Pharmacol Exp Ther 329: 368-376.
18. Khanamiri S, Soltysinska E, Jepps TA, Bentzen BH, Chadha PS, Schmitt N, et al. (2013). Contribution of Kv7 channels to basal coronary flow and active response to ischemia. Hypertension 62: 1090-1097.
19. + channels. Mol Pharmacol 75: 272-280.
20. Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE, et al. (2008). Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 325: 475-483.
21. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA, (2000). Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58: 253-262.
22. Mani BK, Brueggemann LI, Cribbs LL, Byron KL, (2011). Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery. Br J Pharmacol 164: 237-249.
23. McCallum LA, Greenwood IA, Tribe RM, (2009). Expression and function of Kv7 channels in murine myometrium throughout oestrous cycle. Pflugers Arch 457: 1111-1120.
24. McCallum LA, Pierce SL, England SK, Greenwood IA, Tribe RM, (2011). The contribution of Kv7 channels to pregnant mouse and human myometrial contractility. J Cell Mol Med 15: 577-586.
25. Mulvany MJ, Halpern W, (1977). Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19-26.
26. Ng FL, Davis AJ, Jepps TA, Harhun MI, Yeung SY, Wan A, et al. (2011). Expression and function of the K+ channel KCNQ genes in human arteries. Br J Pharmacol 162: 42-53.
27. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y, (2002). Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol 282: G277-G287.
28. Ohya S, Sergeant GP, Greenwood IA, Horowitz B, (2003). Molecular variants of KCNQ channels expressed in murine portal vein myocytes: a role in delayed rectifier current. Circ Res 92: 1016-1023.
29. Padilla K, Wickenden AD, Gerlach AC, McCormack K, (2009). The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett 465: 138-142.
30. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
31. Rode F, Svalø J, Sheykhzade M, Rønn LC, (2010). Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder. Eur J Pharmacol 638: 121-127.
32. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, et al. (1996). D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 23: 211-223.
33. + channel sensitivity to the anticonvulsant retigabine. J Neurosci 25: 5051-5060.
34. Schrøder RL, Jespersen T, Christophersen P, Strøbaek D, Jensen BS, Olesen SP, (2001). KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 40: 888-898.
35. Soldovieri MV, Miceli F, Taglialatela M, (2011). Driving with no brakes: molecular pathophysiology of Kv7 potassium channels. Physiology 26: 365-376.
36. Stott JB, Jepps TA, Greenwood IA, (2014). Kv7 potassium channels: a new therapeutic target in smooth muscle disorders. Drug Discov Today 19: 413-424.
37. + channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 172: 2054-2058.
38. Svalø J, Hansen HH, Rønn LC, Sheykhzade M, Munro G, Rode F, (2011). Kv7 positive modulators reduce detrusor overactivity and increase bladder capacity in rats. Basic Clin Pharmacol Toxicol 110: 145-153.
39. Svalø J, Bille M, Parameswaran Theepakaran N, Sheykhzade M, Nordling J, Bouchelouche P, (2013). Bladder contractility is modulated by Kv7 channels in pig detrusor. Eur J Pharmacol 715: 312-320.
40. Tober C, Rostock A, Rundfeldt C, Bartsch R, (1996). D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 303: 163-169.
41. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: 34.
42. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H, (2005). The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 67: 1009-1017.
43. Yeung S, Schwake M, Pucovský V, Greenwood IA, (2008). Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents. Br J Pharmacol 155: 62-72.
44. Yeung SY, Pucovský V, Moffatt JD, Saldanha L, Schwake M, Ohya S, et al. (2007). Molecular expression and pharmacological identification of a role for Kv7 channels in murine vascular reactivity. Br J Pharmacol 151: 758-770.
45. Yu H, Wu M, Townsend SD, Zou B, Long S, Daniels JS, et al. (2011). Discovery, synthesis, and structure activity relationship of a series of N-Aryl-bicyclo[2.2.1]heptane-2-carboxamides: characterization of ML213 as a novel KCNQ2 and KCNQ4 potassium channel opener. ACS Chem Neurosci. 2: 572-577.
46. Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, Cole WC, et al. (2010). Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol 588: 3277-3293.